Immatics (IMTX) Cash & Equivalents (2019 - 2025)
Immatics (IMTX) reported Cash & Equivalents of $402.7 million for Q4 2025, up 59.16% on a YoY basis from $253.0 million in Q4 2024, and up 2.84% sequentially from $391.5 million in Q3 2025.
Immatics (IMTX) Cash & Equivalents (2019 - 2025) Analysis & Trends
Immatics (IMTX) has 7 years of Cash & Equivalents data on file, last reported at $402.7 million in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents rose 59.16% year-over-year to $402.7 million; the trailing twelve-month figure through Dec 2025 stood at $402.7 million (up 59.16% YoY), and the FY2025 full-year result was $390.8 million, up 52.52% from the prior year.
- Cash & Equivalents advanced to $402.7 million in Q4 2025, from $391.5 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $402.7 million in Q4 2025 to a low of $90.8 million in Q3 2023.
- A 5-year average of $219.0 million and a median of $200.3 million in 2021 frame the typical range for Cash & Equivalents.
- Across the five-year window, Cash & Equivalents sank 54.4% in 2023 and surged 128.74% in 2024, its largest moves.
- Tracing IMTX's Cash & Equivalents over 5 years: stood at $152.1 million in 2021, then declined by 0.4% to $151.5 million in 2022, then surged by 55.13% to $235.1 million in 2023, then climbed by 7.63% to $253.0 million in 2024, then surged by 59.16% to $402.7 million in 2025.
- Business Quant data shows IMTX's Cash & Equivalents at $402.7 million in Q4 2025, $391.5 million in Q3 2025, and $290.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | Immatics | 1.14 Bn | 1.14 Bn | - | 402.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 402.66 Mn |
| Sep 30, 2025 | 391.54 Mn |
| Jun 30, 2025 | 290.50 Mn |
| Mar 31, 2025 | 255.44 Mn |
| Dec 31, 2024 | 252.99 Mn |
| Sep 30, 2024 | 207.78 Mn |
| Jun 30, 2024 | 170.30 Mn |
| Mar 31, 2024 | 132.64 Mn |
| Dec 31, 2023 | 235.06 Mn |
| Sep 30, 2023 | 90.84 Mn |
| Jun 30, 2023 | 161.73 Mn |
| Mar 31, 2023 | 126.57 Mn |
| Dec 31, 2022 | 151.53 Mn |
| Sep 30, 2022 | 179.52 Mn |
| Jun 30, 2022 | 282.90 Mn |
| Mar 31, 2022 | 277.57 Mn |
| Dec 31, 2021 | 152.14 Mn |
| Sep 30, 2021 | 190.21 Mn |
| Jun 30, 2021 | 192.80 Mn |
| Mar 31, 2021 | 235.62 Mn |